| Plegridy (PEG-interferon β-1a) / Biogen |
| Withdrawn | 4 | 0 | Europe | peginterferon beta-1a, PEGylated Interferon Beta-1a, PEG IFN β-1a, Plegridy, BIIB017, brimonidine tartrate, Mirvaso, Vehicle Gel | Biogen | Relapsing-Remitting Multiple Sclerosis (RRMS) | 08/16 | 08/16 | | |
NCT02665221: Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY |
|
|
| Terminated | 4 | 30 | US | No Treatment Arm, Topical Preparation H arm | NYU Langone Health | Multiple Sclerosis | 09/16 | 09/16 | | |
| Withdrawn | 4 | 0 | US | Interferon Beta, Rebif or Betaseron/Betaferon, BIIB017 (Peginterferon beta-1a), PEGylated interferon beta-1a (IFN β-1a) | Biogen | Relapsing Multiple Sclerosis | 02/17 | 03/18 | | |
VITALITY, NCT03091569: Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy |
|
|
| Completed | 4 | 23 | Europe | Vitamin K Cream, Filloskin K1, Placebo Cream | Biogen | Relapsing-Remitting Multiple Sclerosis | 01/18 | 01/18 | | |
